Posted by Michael Wonder on 03 Apr 2019
FDA approves Asceniv, a novel intravenous immune globulin
1 April 2019 - Approved for use in the treatment of primary humoral immunodeficiency disease in adults and adolescents (12 to 17 years of age.
ADMA Biologics announces that the U.S. FDA has approved Asceniv, Immunoglobulin intravenous, human – slra 10% liquid, formerly referred to as RI-002.
The Company anticipates having the product available for commercial launch during the second half of 2019.
